Cachexia-Affected Survival Based on Inflammatory Parameters Compared to Complex Conventional Nutritional Assessments in Patients with Pancreatic Cancer and Other Gastrointestinal Tumors-The CONKO 020 Investigation

• Published in: Cancers Vol. 16; no. 6; p. 1194
• Main Authors: Meyer-Knees, Johanna W, Falkenthal, Janina, Geisel, Dominik, Neumann, Christopher C M, Hilfenhaus, Georg, Stephan, Lars U, Schöning, Wenzel, Malinka, Thomas, Pratschke, Johann, Stintzing, Sebastian, Pelzer, Uwe
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 18.03.2024; MDPI
• Subjects: Adenocarcinoma; Albumin; Biomarkers; Body mass index; C-reactive protein; Cachexia; Cancer; Cancer patients; Care and treatment; Development and progression; Diagnosis; Gastrointestinal tumors; Hemoglobin; Inflammation; Interleukin 6; Interleukins; Malnutrition; Multivariate analysis; Nutrition; Oncology, Experimental; Pancreatic cancer; Patient outcomes; Patients; Product/Service Evaluations; Prognosis; Serum levels; Survival; Survival analysis; Therapeutic applications; Tumors; Germany; CRP; systemic inflammation; PDAC; IL-6; cachexia; survival
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers16061194

Pancreatic adenocarcinoma (PDAC) is still a complex, devastating disease. Cachexia symptoms frequently impair patient survival. This accompanying syndrome is commonly diagnosed late, when clinical signs become evident. Early diagnosis using conventional measurement methods is often difficult, and the discrimination of this disease from cancer progression is challenging and often overlaps. The aim of this study was to analyze whether conventional nutritional assessments or laboratory biomarkers are better predictive tools for the early detection of patients at risk of reduced survival. We analyzed a prospective predefined cohort of 182 patients with gastrointestinal cancer, 120 patients with PDAC and-as controls-62 patients with other gastrointestinal adenocarcinoma (oAC), from whom we have sufficient data of protocol-defined conventional nutritional assessments, clinical data, and specific laboratory parameters. at the time of tumor diagnosis, high inflammatory biomarkers (c-reactive protein (CRP), interleukin-6 (IL-6)) and albumin serum levels were associated with impaired OS in PDAC patients, but not in patients with oAC. Hemoglobin, body mass index (BMI), and bioelectrical assessments alone did not have a prognostic impact at the time of diagnosis. In a multivariate analysis, only CRP (HR 1.91 (1.25-2.92), = 0.003) was found to be an independent prognostic factor in PDAC patients. Over the course of the disease in PDAC patients, inflammatory biomarkers, albumin, hemoglobin, and bioelectrical assessments were associated with impaired OS. In multivariate testing, CRP (HR 2.21 (1.38-3.55), < 0.001) and albumin (HR 1.71 (1.05-2.77), = 0.030) were found to be independent prognostic factors in PDAC patients. Specifically for PDAC patients, high inflammatory index and albumin serum levels potentially represent a sufficient early surrogate marker to detect patients at high risk of impaired OS better than complex conventional methods. These findings could help to identify patients who may benefit from early therapeutic interventions.